<SEC-DOCUMENT>0001019687-14-004732.txt : 20141216
<SEC-HEADER>0001019687-14-004732.hdr.sgml : 20141216
<ACCEPTANCE-DATETIME>20141216143730
ACCESSION NUMBER:		0001019687-14-004732
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141211
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141216
DATE AS OF CHANGE:		20141216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		141289322

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
December 16, 2014 (December 11, 2014)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 32%; font-size: 10pt">&nbsp;</td>
    <td style="width: 5%; font-size: 10pt">&nbsp;</td>
    <td style="width: 29%; font-size: 10pt">&nbsp;</td>
    <td style="width: 5%; font-size: 10pt">&nbsp;</td>
    <td style="width: 29%; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></td>
    <td style="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">000-21846</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></td>
    <td style="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 55%; font-size: 10pt">&nbsp;</td>
    <td style="width: 3%; font-size: 10pt">&nbsp;</td>
    <td style="width: 42%; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9635 Granite Ridge Drive, Suite 100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P></td>
    <td style="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">92123</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Zip Code)</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 97%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
</table>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Form 8-K and other reports filed by
Registrant from time to time with the Securities and Exchange Commission (collectively, the &quot;Filings&quot;) contain or may
contain forward-looking statements and information that are based upon beliefs of, and information currently available to, Registrant's
management as well as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate,&rdquo;
&quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;future,&quot; &quot;intend,&quot; &quot;plan&quot; or the
negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward-looking
statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties,
assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses
that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions
prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although Registrant believes that the expectations
reflected in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance
or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not
intend to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ITEM 8.01 OTHER EVENTS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 11, 2014,
the Registrant issued a press release announcing the initiation of patient recruitment to support a clinical feasibility study
of Hemopurifier<SUP>&reg;</SUP> therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the press
release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">EXHIBIT NO.</font></td>
    <td><font style="font-size: 10pt">DESCRIPTION</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">99.1</font></td>
    <td><font style="font-size: 10pt">&ldquo;Aethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study&rdquo;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 46%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 48%"><font style="font-size: 10pt">AETHLON MEDICAL, INC.</font></td></tr>
<tr>
    <td style="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</td>
    <td style="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:&nbsp;<u>/s/ James A. Joyce</u></P></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">James A. Joyce</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Dated: December 16, 2014</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Chief Executive Officer</font></td></tr>
</table>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 54pt; width: 144.6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical Initiates Patient Recruitment
for FDA Approved Clinical Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO, December 11, 2014 /PRNewswire/
--Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and
cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier<SUP>&reg;</SUP>
therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas. The study, which will enroll individuals infected
with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device
Exemption (IDE) approved by the United States Food and Drug Administration (FDA). A detailed description of the study, including
treatment protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Aethlon Hemopurifier is a first-in-class
bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system
of infected individuals. To date, Hemopurifier therapy has been administered outside the United States in the treatment of Ebola,
HIV and HCV-infected individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the feasibility study protocol, Aethlon
will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety
of Hemopurifier therapy in an infectious disease model. Upon successful completion of the feasibility study, Aethlon plans
to conduct pivotal efficacy studies required for market clearance to treat chronic viral indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The feasibility study will also contribute
safety data to advance Hemopurifier therapy as a broad-spectrum countermeasure against category &ldquo;A&rdquo; bioterror and pandemic
threats that are not addressed with proven drug or vaccine therapies. The virulence of such viral threats does not permit for human
pivotal (efficacy) studies to be conducted. &nbsp;In the treatment of Ebola virus, Hemopurifier therapy is available in the US
under emergency-use IDE regulatory provisions. The Company plans to pursue Humanitarian Use Device (HUD) approval pathways for
Ebola and orphan indications that affect fewer than 4,000 individuals in the U.S. each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Previously, <I>in vitro</I> studies of
bioterror and pandemic threats have verified Hemopurifier capture of Ebola hemorrhagic virus, dengue hemorrhagic virus, lassa hemorrhagic
virus, H5N1 avian influenza (bird flu), the reconstructed 1918 influenza virus (r1918), 2009 H1N1 influenza virus (swine flu),
West Nile virus, and monkeypox, which serves as a model for human smallpox infection. These studies were conducted with leading
government and non-government research organizations, including The U.S. Army Medical Research Institute of Infectious Diseases
(USAMRIID), The Centers for Disease Control and Prevention (CDC), The National Institute of Virology (NIV), The Battelle Biomedical
Research Center (BBRC) and The Southwest Foundation for Biomedical Research (SFBR).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical creates targeted therapeutic devices to
address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon
Hemopurifier&reg;,&nbsp;a first-in-class device that selectively targets the rapid elimination of circulating viruses and
tumor-secreted exosomes that promote cancer progression. &nbsp;Exosome Sciences, Inc. is a majority owned subsidiary that is
advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders.&nbsp; For
more information, please visit <FONT STYLE="font-size: 10pt">http://www.aethlonmedical.com/</FONT> and connect with the
Company on <FONT STYLE="font-size: 10pt">Twitter</FONT>, <FONT STYLE="font-size: 10pt">LinkedIn</FONT>, <FONT STYLE="font-size: 10pt">Facebook</FONT>
and <FONT STYLE="font-size: 10pt">Google+</FONT>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Certain statements herein may be forward-looking
and involve risks and uncertainties.&nbsp; Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA
will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT&trade; system or the Aethlon Hemopurifier&reg; as
an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or
hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital
when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its
products either internally or through outside companies and provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors.
In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with
the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission
filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result
of new information, future events, or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #262626">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #262626"><B>Aethlon Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leah-Michelle Nebbia (for interviews requests)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Golin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">202-585-2651</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">lnebbia@golin.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James A. Joyce<BR>
Chairman and CEO<BR>
(Office) 858.459.7800 x301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Cell) 619-368-2000<BR>
jj@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes<BR>
Chief Financial Officer<BR>
858.459.7800 x300<BR>
jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`"O`=8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HK%U3Q;HFD
M%DN;Y&E7_EE%\[9]#CI^.*Y>]^*J`E;'3&8=GGDQ_P".C/\`.NFGA:U36,3&
M=>G#=GH5%>23_$K7Y3\GV6'_`'(L_P`R:J?\)]XG_P"@G_Y`C_\`B:ZEE==]
M5_7R,7C:?F>S45XY%\0?$J-EKY9!Z-`F/T`K1M?BCJT9'VFSM9U_V0R'\\D?
MI2EEE=;68+&4WW/4J*XS3_B=I%QA;R">S;N<>8H_$<_I7566H6>HP^;9745P
MG<QL#CZ^E<=2A5I?'&QT0JPG\++-%%%8F@4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!117`^+_`!]]E9].T9PTH^66
MY'(3V7U/O_D;4:$ZTN6",ZE2--7D=#X@\7:9X>79,YFN2,K;QGYOQ]!7FFM^
M--8UHLC3FVMC_P`L820"/<]3_+VK!DD>61I)'9W8Y9F.23ZDTVOH</@:5'5Z
ML\FKB9U--D%%%%=YSA1110`4444`%36MW<64ZSVL\D,J]'C8J:AHI-)Z,#OM
M!^)DT;+!K<?FIT^T1+AA]5Z'\,?0UZ'9WMMJ%LES9SI-"_1T.1_^NOGZM30_
M$%_X?NQ/9R?(3^\A;[D@]QZ^]>7B<NA-<U/1_@=M'%RCI/5'NE%9/A_Q%9>(
MK+S[9MLJ\2PL?F0_U'H:UJ\"4)0ERR5F>I&2DKH****D84444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!117-^-?$@T#2=L##[9<Y6'_9'=OP
M_F:NG3E4FH1W9,YJ$7)F'X\\8M"7T;3)</C%S,I^[_L`^OK^7K7F]*S,S%F)
M+'DD\Y-)7U>'H1H0Y8GAU:CJ2YF%%%%=!F%%%%`!1110`4444`%%%%`!1112
M`N:7JEUH^H1WMG)LDC/([,.ZGU!KVG0-=MO$&F)=V_RM]V6,GF-O3_`UX56S
MX7\02^'M62X!8V\F%GC'\2^OU'4?_7K@QN$5:/-'XE_5CIP]=TY6>Q[?13(9
MH[B%)H7#QR*&5AT(/0T^OF3V0HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBN6^('C%_!.A0ZG'9+>&6Y6#8TFS&59LYP?[OZT`=317GGP_P#B
MC+XVUV?3)-)2S$5LT_F+.7SAE7&-H_O?I7H=`!1110`4444`%%>5^+/C+/X:
M\3WNC)HD=PMJRJ)3<%2V5#=-I]:[_P`,:RWB'PW8ZNT`@-W'O,8;=MY(ZX&>
ME`&K1110`4444`%%%%`!1110`4444`%%%%`!1110`UV5$+NP55&23T`KP_Q-
MK3Z]KD]YD^5G9"OH@Z?GU_&O2?B%JIT[PU)"AQ)>-Y(QV7JWZ<?C7D%>[E=&
MR=5^B/,QM2[4$%%%%>R<`H!9@J@DDX`'>NVT[X8:A=6JS7=Y':.XR(MA<@>_
M(P:/AQX>%[?'5[E,PVQQ$".&D]?P_F1Z5ZC7C8W'2ISY*;VW._#893CS3/./
M^%4R_P#083_P'/\`\51_PJF7_H,)_P"`Y_\`BJ]'HK@_M#$_S?@O\CJ^JTNQ
MYQ_PJB7_`*#"?^`Y_P#BJ/\`A5$O_083_P`!S_\`%5Z/11_:&)_F_!!]5I=C
MS2?X57:Q$V^J0R/V5XR@/XY/\JXJ^L;G3;R2TNXFBFC.&4_YY%>I^/?B!9^!
M;2W:2U:\NKICY5NLFSY1C<Q;!P.1VY_/&'K5QIOQ`\()XDT=6\^T)66-@-Z@
M<LK8],[A[$^M=>%S";J*-5W3.>OA8J/-#H<!1117NGG!1110`4444`>F_#/7
M3<V<NCSME[<;X23U0GD?@3^OM7=UX1X?U0Z/KEK?`D+&X\P>J'AOT)KW8$,`
MP.0>017S68T?9U>9;,];"5.:'*^@M%%%><=@4452UC4!I.B7VI&/S!9VTD^S
M.-VQ2V,_A0!=HKY^D^+_`(\UZ<VVC6L44G54LK0S28SWW;L_D*F5_C1J:"8#
M4T'H5C@//^R=I_2@5SWNBOG:^\4?%;PN"VHSZA!&#S)/;I)'D]MY4CMZUUW@
M3XSOJ^IP:3XAMHHI;AQ'#=0`JFX]`ZDG&3W'<C@=:`/6Z**YWQ/XQLO#BB+;
M]HO&&5A5L;1ZL>U73IRJ2Y8J[%.<8*\CHJ*\H3Q;XQUZ<KIRLH'5;:`$+]6.
M<?G4\D_Q%L4,[BZ91R<)'+^@R:[7@)K24XI]KG-];B]5%V/4**\[T/XF,TRV
M^M0(JDX^T1`C;_O+_4?E6_X\U^ZT'P+?:UI<D1GB6(Q.PWJ0TBKGWX8US5L/
M4HNTT;4ZL*BO$Y7XP^,]=\*R:7#HMVMK]I61I&\I7)V[<?>!`ZFK?P9UO4]>
M\/ZC=ZK?37<WVT@-*V=HV+P!T`]A7BGBCQEK'B^6WDU>6)S;*PC\N,)C.,]/
MH*L>&?'^O^$K*6TTF:%(II/,821!OFP!U^@%8&A]3UYE\>O^1'L_^PDG_HN6
MN0\-_%[Q9J7B?2K"YGM6@NKR*&0"``[6<*<'Z&NO^/7_`"(]G_V$D_\`1<M`
MSC/@+_R/%Y_V#7_]&15]`5\\?!.^M=,\5:G?7LRP6\&E2/)(W10)(JT?$_QT
MU.ZF>#PW;I96XX%Q.@>5O<*<JOT.?PZ4`>[45\PW'Q`\>R1_:Y=8OTB;I(L8
M1#],`"KFF?&3QEI\P::^BOX@,>5<PKCZY4!L_C0(^DJ*Y?P/X[T_QOI\DMM&
MUO=6^!<6SG)3/0@]U.#SQTZ5U%`SY@^*G_)2M8_ZZ)_Z+6O=_AK_`,D[T7_K
MW_J:\(^*G_)2M8_ZZ)_Z+6O=_AK_`,D[T7_KW_J:!'4445YCXV^,MEH-S+IN
MAP)J%[&=LDSD^3&W<<<L1WP0/?J*!GIU%?-A^)'Q#UZ:2.RO;E^<^58VJ_(/
MJJEL<=S39_&_Q*T'#7M[J=IO.!]LM1@G'0;UH$?2M%>,^%?CL7N%MO%%I''&
MW`O+56^7I]Y.2>YROY5[%!/#<P1W%O*DL,JAXY$8,KJ1D$$=010,DHJKJ=P]
MII5W<Q8\R&!W7(R,A217AOASXN^+=2\3Z587-Q;&"ZO889`MN`2K.`>?H:`/
M?**\M\=_&2+0;Z72M!MXKR[A)6:>4DQ1L#RH`P6/7/(`/KSCSB3XD>/]5+/%
MJMVRH<D6T"J%]OE7^=`'TS17S#:?%7QM9L-FN22*#DK-$CY]LE<_D:]1^'_Q
M>B\2WT>D:U;Q6=_+GR98L^5,?[N#DJV.G)!YZ'`(!Z;1110!Y7\3[XS:[!9@
M_+;0Y/LS')_0+7%UL^+KC[5XLU*3.<3F/_OGY?Z5C5]=AH<E&,?(\&M+FJ-A
M4]C93:C?0V=NNZ69PBCZ]_I4%>C?#/0=J2:W.G+9CM\CM_$W]/SHQ-94:;F%
M*FZDU$[;2M-ATC3(+"W'R0IC./O'N3]3DU<HHKY)MR=V>ZDDK(****0PJ.XN
M(;6WEN;B18H84+R2.<!5`R23Z`5)7E7QO\6_V?I,?ARTE(N+X![G:>5A!X'_
M``(C\E/K0!Y-XU\3R^+O$]SJK[EA)\NVC;K'$/N@]>>I/N36S\*/%:^&O%2P
M73A=/U(""XW=%;^!C]"2#VPQ-<110![#XOT(Z#KLL2+BVF_>0'MM/;\#Q^58
M5=?X=O\`_A8GPW$+GS-:T7"$DY:08^4Y/)W*,'U92:Y"OJ,%7]M2UW6YXF(I
M>SGILPHHHKN,`HHHH`*]M\'7QU#PK8S,<ND?E-D\Y4[?Z`UXE7J7PNN#)H5U
M;DY\JXR/8%1_4&O,S.%Z/-V9UX.5JENYVU%%%?.'KA4%[9V^HV4UG=Q"6WG0
MI(A)PRGJ.*GHH`KV.GV6F6PMK"T@M(%)(B@C"*/7@58KG-=\?^%_#DC0ZCJT
M(N%.#!%F20'K@A<[?QQ7"ZI\?K%`5TC1)YB1]^ZD$8!_W5W9_,4`>KWD5M-9
MS17J1O;/&1,LH!0ICG.>,8KY`O#;IJ$YL7<VZRMY#-PVS/RD^^,5W5WXA^(?
MQ-!LK6WE:S8@/%9Q^5!D?WW)_1FQP.*X6^LY-/U"YLIBIDMI6B<J<@E20<>W
M%`CZTU#5%TS0)=3FP?*A#XZ;F(X'XD@5Y#H]C<^*_$J13RLS7#F2>3N%')_P
M'X5W?Q!G:+P5;(O2:6)&^FTM_-17!>'-0U;3;R2XTBU:>8Q[&Q"9,*2#T'3I
M7N8"FXX>4X_$SS<3*]51>R/:;*RMM.M([6TA6*&,855'^<GWJQ7F/_"7>-_^
M@8__`(!/1_PEWC?_`*!DG_@$]<;P-5N[DOO.A8J"T2?W"_$S1(;2X@U6WC""
MX8I,!P"_4'ZD9S]*U_ACJLEWI-QI\K%C:.#&3V1L\?@0?SKEM:U+Q7K]FEK?
M:7/Y:2"0;+1P<@$?U-;GPSL+RSO;YKJTG@#1J`98RN>3TS795C;!\LVFU_F<
MU.5\1S16C.6_:"_X_-#_`.N<W\TK:^`?_(J:C_U_'_T!*Q?V@O\`C\T/_KG-
M_-*VO@'_`,BIJ/\`U_'_`-`2O#/3/4J\R^/7_(CV?_823_T7+7IM>9?'K_D1
M[/\`["2?^BY:!GA>EVE[J6H1:98;C-?.L`0,0'RP(#>V0#[8SVKZ8\'_``^T
M3PA9Q""VCN+\+^]O94!=F[[?[H]AVZY/->/?!&PCO/B`)GZV5I),GU.U/Y.:
M^BJ`"O*_B]X`TV?0;CQ%IMJMM?6F'G6%`%G0GDD#C<,YW>@(.>,>J5@>//\`
MD0M<_P"O&7_T$T`>#?"/49-/^(VGJLA2.Z#P2C^\"I('_?04_A7TQ7RQ\.?^
M2A:)_P!?2_UKZGH`^8/BI_R4K6/^NB?^BUKW?X:_\D[T7_KW_J:\(^*G_)2M
M8_ZZ)_Z+6O=_AK_R3O1?^O?^IH$9/Q>\6S>&O"RVUC*T5]J3&*.13AHT`^=@
M?7D#L1NR.E>3_"_P/'XSUV0WI8:;8A7N`IP9"<[4SU`.#DCL.Q(-:_QYNGD\
M96=MO;RX;%2%/0,SODCZ@+^5=S\#;+[-X#:X(YN[R23..P"KC\U/YT`=]8Z?
M9Z9:):6%K#:V\?W8H4"J/7@5-)&DL;1R(KHXPRL,@CT(IU%`SPCXO?#JUT-%
M\0:+`(;.239=6Z`[8F/1E'92>,=`<8Z\:7P*\52R?:/"]T^Y(T-Q:$_PC/SI
MU]6#`8_O>U>B>/K2*]\`ZY%,H95LI)0#_>1=Z_JHKYY^'%^=.^(6B3@$[[H0
M\#_GH#'_`.S4`?3.N?\`(!U#_KUE_P#037R+;7$UG=175O(8YH7$D;KU5@<@
MC\:^NM<_Y`&H_P#7K+_Z":^2M+LCJ.K6=B&VFYG2$-Z;F`_K0(]I^%?PQTY=
M'M_$&NVB75S=*);:"4!DCC/W6*]&)!SSTXZ&O65544*H"J!@`#@"D1$BC6.-
M0J(`%4#@`=J=0,Y_Q7X,T?Q=I\D%]:QBYV$0W83]Y$V.#GJ1G^$\&OEV>&[T
M;5I(68PW=E.5)4\I(C8X/L17V%7R9XS_`.1XU[_L)7'_`*,:@#ZHTF^75-'L
MM0086[MXY@/0,H;^M6ZQ?!G_`"(^@_\`8-M__1:UM4`>!ZNV_6KYR,%KB0_^
M/&J=7=90QZY?QG^&YD'/^\:I5]G#X4?//<OZ+I4VM:M!80Y!E;YFQ]Q>I/Y5
M[G:VT-E:Q6L"!(H4"(H[`5R/PXT'[#IC:I.N)[P?N\_PQ]OS//T`KM*^=S#$
M>TJ<JV7YGJX2ER0YGNPHHHKSCL"BBB@"IJNIVNC:7<ZE>R".WMHS([>P[#U)
MZ`=R:^3_`!#K=SXCUZ\U>[XENI"VT=$7HJ_@H`_"O4_CKXJ??;^%[5R$P+B[
M(/WO[B=?JQ!']WTKQN@`HHHH`Z;X?^*W\(>*K>^9C]DE_<W:^L9/)Z'E3AN.
MN,=Z]&\>:&NF:Q]LM@#:7V9$*]`W\0_7(^OM7B=>U?#S5$\;^!;CPK=N/[1T
MQ0]HS$9:,<+[_*?E/'`9>]=>#K^QJIO9[G/B*7M(:;G,T4Z2-XI&CD4JZ$JR
MD8((ZBFU]4>*%%%%,`KT7X4$[=57)P/)('_?=>=5Z-\*$8)JCD?*3$!]1O\`
M\17#F'^[2^7YHZ,+_&7]=#T*BBBOESV@KQKXR?$"_LK_`/X1C2+A[;:BO>31
M,5<D\B,'L,8)QUR!TSGV6OFKXQVTT'Q*U&26,JEPD,D1/\2^6JY_[Z5A^%`#
M_`'POOO&:F_N)C8Z6C[?-VY>8@\A![=-QX!['!Q[-HGPQ\(Z$JF'28KJ8``S
M7G[YB1WP?E!_W0*I?"#5[#4/`-G:6LD8N+'='<0@_,A+,0Q'HP.<],Y&<@UW
M-`"*JHH50%4#``'`%?)'BC_D;-8_Z_I__0S7UQ7R/XH_Y&O5_P#K^G_]#-`'
MT+X_MVG\$P2+T@DBD/TP5_\`9A6!\+KE8]<NK8\>=;Y'N5(X_(G\J]#FL8]2
MT(V4WW)[<(2.V1U_"O&D-_X4\1*S+MN;.3IV<?X$?SKV<':MAYT>O]?J>=B/
MW=6-3H>Z45EZ)X@T_7K59;2=?,QEX6/SH?<?UK4KR)1E%VDK,]",E)7045%<
M75O:1&6YGCAC'5I'"C\S3;.]M]0M5NK242PN2%<=#@D']0:5G:_0+J]CQK]H
M+_C\T/\`ZYS?S2MKX!_\BIJ/_7\?_0$K&_:"!^UZ$V#@I.`?Q2IO@+KMG%!J
M&A33)'<R2B>!6.#*-N&`]2-H./?V-(#V6O,OCU_R(]G_`-A)/_1<M>CW%U;6
MB![FXBA5B%!D<*"3T'-><?'K_D1[/_L))_Z+EH&<9\!?^1XO/^P:_P#Z,BKZ
M`KY_^`O_`"/%Y_V#7_\`1D5?0%`!6!X\_P"1"US_`*\9?_036_6!X\_Y$+7/
M^O&7_P!!-`,^=_AS_P`E"T3_`*^E_K7U/7RQ\.?^2A:)_P!?2_UKZGH$?,'Q
M4_Y*5K'_`%T3_P!%K7N_PU_Y)WHO_7O_`%->$?%3_DI6L?\`71/_`$6M>[_#
M7_DG>B_]>_\`4T`>5?'JSDB\7V-WL(BGL@H;U97;(_)E_.NU^!E^+KP/+:%A
MOL[MUVYY"L`P..W);\C5[XM>$9/$_A7SK.(R7^G$S0HHRTBD?.@'J0`1ZE0.
M]>._#7QM_P`(9K[27`9M.O%$=TJC)7'W7`[D9/'H3WQ0!].454TS5=/UFR2]
MTV\BNK=QP\39'T/H?8\BIKBX@M+>2XN9HX88U+/)(P55'J2>`*!F%\0;V*P\
M`:Y-,<*UG)"/]Z0;%_5A7SY\-K#^T?B'HL/9+@3?]^P7_P#9:ZCXN?$6W\1.
MN@Z/)YEA;R;YKA3Q.XX`7U49Z]SR.`"=WX&^$IK6*X\3WD93[0GDVBMW3.6?
M'N0`/HWJ*!'J6N?\@#4?^O67_P!!-?+7@S_D>-!_["5O_P"C%KZEUS_D`ZA_
MUZR_^@FOEKP9_P`CQH/_`&$K?_T8M`'UG1110,*^3/&?_(\:]_V$KC_T8U?6
M=?)GC/\`Y'C7O^PE<?\`HQJ`/IGP9_R(^@_]@VW_`/1:UM5B^#/^1'T'_L&V
M_P#Z+6MJ@#Q+QG;?9?%VH)MP&E\P>^X!OZTSPMHC:]KD-H0?)7]Y.1V0=?SZ
M?C70_%&P,6JVE^H^6>(QL<?Q*?\`!A^5=1X#T'^QM#6:9,75YB23/55_A7\C
MGZDU]#+%<F$C);M6/)C0YJ[B]D=*B+&BHBA548``X`IU%%?/'K!1110`52U?
M4X='TN>_G^["N0N?O'L/Q-7:\N^).O?;-032('S#:G=+@\-)Z?@/U)]*Z<+0
M=:JH].IC7J>S@WU/-O%\<VL&;5)3ON0Q=SZJ>OY=O;-<;7HA&00>0:XC5[`V
M%^\8'[MOFC/MZ?ATKT,RPRC:K%:;/]#EP=6_N,I4445XQZ`5L>%/$,_A;Q)9
MZO!N(A?$L8/^LC/#+^73T.#VK'HH`]T\>:;;R/;>(].8266I(K[EZ;B,@_B/
MU!KCZV_A)K4&O:!>^!]1<`A6ELF..`3E@/<-\WOENPK*O+2:PO)K2X7;+"Y1
MA[C^E?1Y=B/:4^1[K\CR,52Y)\RV9#1117IG(%>J?#"V,7AZ>=ACSK@X]P`!
M_/->5U[EX6L#IGAJQM6&'$0=P>S-\Q'YFO+S.=J*CW9V8.-ZE^QK4445\Z>L
M%<CX^^']CXXLH]TOV2_M\^1<A=PP>JL.X_4'GU!ZZB@#YS;X5_$'0+XS:9$6
M=%P+FPO`AY[#)5OTK0_L?XSSQ>1YNJ!<`9^W1H>/]K>#^M>^44`<%\+?"^NZ
M%:ZC>^)))6U&^D0$2SB9@B`XRP)Y)9N_85PFM?!;Q3J&N7][#+IXBN+F25-T
MS`X9B1GY?>O>**!6(X$,=O'&V,J@!Q["LKQ#X7T_Q'`!<@QSH,1SI]Y?8^H]
MJV:*J$Y0ES1=F*45)69Y->?#C7[*7?9-%=!3E6CDV-^1QC\S3/\`A'O'3*$V
MWNWT-X,?^A5ZY17H+,JMO>2?R.7ZG#HV>2Q?#SQ+>OONC#$QZM//N/\`X[FO
M3='L/[+T>TL<AC!$%8J.">Y_/-7:*YZ^*J5TE+9&M*A"D[HY/XA^"(_&^AK;
MI*D%];,9+69QQDC!5N^T\9QW`/.,'Q&Y^$GC>WF9!HWG*"0'BN(RK>X^;/Y@
M5]-45RFY\]^%/A/XNB\2Z9>7^F1VUK;W44TK2W"'*JP)`"DG.!Z5ZE\3_">H
M^,?#=OI^F/`LT5XLQ\]RHVA'7L#SEA7944`>6?"_X;:YX/\`$EQJ.IR6;0R6
M;0J(9&9MQ=&[J.,*:]3HHH`*RO$^FSZQX8U/3;8H)KJV>*,N<+DC`R:U:*`/
M$O"/P@\2Z'XKT[5+N6P,%K,)'$<S%L>PVU[;110!XOXW^$OB/Q#XPU#5K*6Q
M%O<NI022L&X11R-I[BO3O!^D7.@^$].TN\,9GMHMCF,Y7.2>#Q6U10*P5YMX
MW^#NG^(KB;4](F73]0E.Z1&&89FYY('*DG&2,_3))KTFB@9\W2_"?Q[I-V7L
M[+S"GW;BTNT7/TR0WZ4V7X:_$75YE-[87,Q!QYEU>HVW/?E\]NU?2=%`'D'A
M3X%Q6MPEWXFNX[K8<BSMB=A]-SG!/T`'U/2O7(HHX(DABC6..-0J(@P%`X``
M["GT4`5M2MWN]+N[:,@/-"\:YZ9*D"O$_#WP:\4:7XDTO4;B73S#:7D4T@29
MB=JN&./EZX%>ZT4`%%%%`!7A7B'X,^*-4\2:IJ%O-IXAN[R6:/?,P.UG+#/R
M]<&O=:*`,[P]83:7X;TS3K@J9K2SBAD*'*EE0*<>V16C110!0U71[368X([Q
M-RP3+,H]2.Q]CFK]%%-R;20DDG<****0PHHHH`R?$NM)H.B37A(\W&R%3_$Y
MZ?X_05X?)(\TCRR.7=V+,S'))/4FNH\?Z]_:VM&UA;-M9$HN/XG_`(C_`$_#
MWKE:^FP&']E2N]V>-BJO/.RV05G:Y8?;K!BBYEB^9,=3ZC\?YXK1HKLJ0C4B
MXRV9A"3A)21YW16GK]A]COBZ#]U-EE]CW'^?6LROD:M-TIN$NA[L)J<5)!11
M1699<TC5;O0]6M=4L7V7%K()$/.#CJ#CJ",@CN":]L\80VNOZ)8>,=+&8;J-
M1..I4]!G'<$%3[@5X/7J7P:\1Q/-=>#M3.ZSU%6:WW'[LF/F4<<9`SUX*^K5
MOAZSHU%-&5:FJD'$HT5=U?3)M'U2>PG'S1-@-_>7L?Q%4J^MC)22:/"::=F:
M_A;23K7B&UM2NZ(-YDWIL7D_GT_&O<:XWX<Z"=.TEM1G0B>]`*@_PQ]OSZ_E
M795\WF%;VM6RV6AZ^$I\D+O=A1117GG6%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!6'XK\1-X:T^*Z6U%QYDOE[2^W'!.>A]*W*XGXI?\@"T_Z^A_Z"
MU=&&A&=:,9;,RK2<:;:-KPKXD7Q+I\MQY`MY(I-C1A]W&`0<X'O^59OBCQT/
M#VJ+8Q62W+>6'=C+MVDYXZ'M@_C67X?8>'/B#J.ER$1V]T&=,\`8^=?R!85S
MM\IUJTUOQ'*IP9TCASVR?YA0H_&N^GA:3K-M>Y96^>WZG)*O-4TD_>UO\CT:
MY\2M;^#5\0?90S&-'\G?@?,P7KCW]*PK;Q_K%Y")K7PK<3QDX#Q%V4_B$I=1
M_P"20)_UPA_]&+6?X2UCQ!9Z#'#I^A?;(`[$2^9C)SR*F%"G[.4N5-J36KMI
M]XY59<T5>VG8Z_0-:O\`5;>YEOM(FTYH<;5E##?P>F0*YNT^(VIW^_[%X:EN
M=F-_DNS[<],X7CH:Z[3+J^O-),VH6?V.<[@8MV<#L:XSX3_\Q7_MC_[/6<(T
M^2I.4=K:7?H7*4^:$5+>Y>@^(WD7BV^M:-<:<&Z.V21[E2`<?3-;OB3Q`-"T
M9=2BA6Z5G55&_`(()SG!K-^(]O!+X5>611YD,J&(]P2<$?D3^5<]J<LDWPDT
MYI"2PE"C/H&<#]`*J%&E54)J-DW9H4JE2'-%N^E[G=:3K":AH$.K3JMLCQF1
MP6R$`)SS^%<U)\0IKV\:WT+19[X)U<Y''K@`X'UQ5'4)I(OA':"/($FU'(]-
MY/\`05T'P_M8(/"5K)$`7G+/(P'5MQ'Z``5+I4J<)5)*_O-)#4YS<8)VTNQ^
M@^(-6U#46M-2T*6Q7RRZRG=M)!`QR/<]^U7_`!!K46@:1+?R)YA4A4CSC>QZ
M#^OX5IUY=\0=:AO?$$&FN[FSLV'G>7R2Q^]CMD#CZYK.A3CB*R2C9=2ZLW2I
MZN[.F\+^-QXAU"2RFLQ:R"/S$_>;MX[]AV(-:'BKQ`WAO3([Q;87!>81;2^W
M&58YS@_W:\YU+Q'I_P#PE=IK6D030K"$$D<B*,X^4XP3U7BNK^)<L=QX4LYH
MF#QR72,K#H04<@UT3PL57I^[:,NAC&M)TY:W:ZG4Z1?G5-)MKXQ^69XP^P'.
MW/O5VL?PE_R*FF_]<%K8KS:B49M+N=D&W!-A4-Y/]ELI[@+N\J-GVYQG`SBI
MJIZM_P`@>]_Z]Y/_`$$THJ\DBI.R9E>$O%#>)H+F1K06WD,JX$F[.<^P]*Q;
M3XF1RZLEG=V"V\)D,;3>=G;V!(QTS3/A5_QYZC_UT3^1KG=$\.CQ#%KD<8Q=
M0,KP'U.6ROX_X5ZWU>@JE136BM\KGGNK5<(.+U=_P/5=4O3IVE75\$$GV>)I
M`N<;L#.,U4\.:W_;NC+J+PBWW,P*[]P&#US@5R&C>(6O_!6JZ3>$B\L[20#?
MP60`C\QT/X4:;-);_"*[>+.XETX]&<*?T)KG>%Y8N+WYDK^3-?;WDFMK-FC>
M?$(2WYLM#TR74G!^^,@'W``)(]SBKFC^)-:N]5AL]1\/36D<V[$_S;5(!//&
M.<>M5?AE:6\7AZ2Z0`S33,)&QR`,87^OXUV537=&G)TXPVTO=W*I*I-*;E\@
MHHHKA.H*Y[QKKW]AZ$YB?%U<9CA]1ZM^`_7%=`2`"2<`=37BOC#73KVNR2QM
MFVA_=P#_`&1U/XGGZ8KNP.']M5UV6YS8FK[.&F[,+.31117U!XP4444`5-4L
M1J%B\/1Q\R$]F'^<5PS*58JP((."#VKT2N<UK0YYKWS[.(.)!EQN`PWX^O\`
MC7DYCAG42J05VCNPE91;C)Z'/45H_P!@:I_SZ_\`D1?\:/[`U3_GU_\`(B_X
MUXWU>M_(_N9Z'M:?\R^\SJDMKF:SNHKJVD:*:!UDC=>JL#D$?0BKO]@:I_SZ
M_P#D1?\`&C^P-4_Y]?\`R(O^-'U>M_(_N8>UI_S+[SVC6)X/''@JS\66*J+F
MW7R[V)>J$?>'X$Y'^RV:S?!GAEM?U,/,I%E;D-*W9CV0?7O[?A53X+IK=EK%
MYI=Q8/+I-Y$3.2P*1.`<$C/\0RI`Y/'85[+INF6FD6*6=E%Y<2=NI)[DGN:Z
MXXRI1HNDU9]/)',\/&I4YT]"T`%4*H``&`!VI:**\T[0HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"N2^(FG7FI:-;165M)<.MP&*QKD@;6Y_6N
MMHK2E4=*:FNA%2'/%Q9PGQ#T"^O;JTU#3+>664(T4HB'..H_FP_*DN_#MW;_
M``UBT^"U>2[D=99(U7+;B<G(]A@?A7>45O'%S4(P_E=S)X>+E*7<X^^TV]D^
M&"Z>EK(UV(8AY(7YLAU)X^@K)T#4/$^@:4EA'X:FF569M[`@\G/I7HU%$<5[
MKC**:;OU!T-4T[65C$T/4M4U2UN3J6EM8.G$:G/SY!]:X?PN/$OAG[5Y7AZ>
M?[3LSN4C&W/_`,57J=%*&)45)<JM*VFO0)47*SYM4><W^G^+?&5Q##?6BZ=8
MHV[#<`=LD9RQQG'0?2MGQAHLO_"'0:9I=M)-Y$D85$&3@`\UUM%-XN7-%I)*
M.R#V"L[N[?4YK2]"^V^`X-(OXWA=HB&###(VXD''UQ7/:8OBSP89+1=,.I61
M;<GE9;!]1C)'N"*]&HI1Q+7,I)--WL-T%HT[-'(VGB;Q#=BXD?PW-;QQ0LR!
ME8L\G`4#('<\\=`:J>`?#MW;3WFJ:M;NES*VQ!,OS<\LWXG'Y&NYHH>(M&48
M12N"H^\I2=['/>,M#&K^'9HH(0UQ$1+$%')(ZC\03^.*Y.[T_7+WP#:Z;+IM
MS]IM+P!5*')CVM@_@3C\J]-HITL5*G%1M>SN*=!3;=[75C@-+UOQ3I>F6]BO
MA>618$"!CN!./PK3O_&-WI6@V][?:48[N>8QBU9RI`'\6<?3\ZZRJ-[H^GZA
M=VUU=VXEFM&W0DLP"'(.<`X/0=?2CVU*<KSA]U_\Q>RJ1C:,B>SDGFLX9;F$
M03.@9X@V=A/;-,U.-Y=+NXXU+.\#JJCJ25/%6J*Y;V=SHMI8XOX<:7?:9:WR
MWUI+;EW0J)%QG@TSP!I5_IVH:L]Y:2P+*R^677&[ENGYBNWHKIGBI3Y[KXK?
M@8QH*/+KM?\`$\\\<>$[QM0&JZ-!([7`*7$<0YR1@MCT(R#_`/7K:\):/)_P
MA9TS4[=XO-,BNC##`$]:ZFBB6*G*DJ;Z=>H*A%3<UU/.+&P\4^"+J9+.S_M.
MPD.XB,$Y/K@<J<>Q'UK>TCQ'K^IZI#!/X=EL;8D^;+,&X`!(QD#O@5U-%.>)
M52[G!7[ZBC1<-(R=NQSUQJ6OIXMBLH;$-I;;=\_EDD?+SSG'7VKH:**YYR4K
M65K&T8M7UN<C\0]>_LS1_L$#XN;T%>.JQ_Q'\>GY^E>2U[QJ^AZ=KEOY-_;B
M3'W''#I]#7G&M_#C4[`M+IQ^W0#G:.)%'T[_`(?E7LY?B*,(<CT9YV*I5)2Y
MMT<=13Y8I8)6BFC>.13AD=2"/J*97LG`%%%%,`HHHH`***T-+T+4]9DV6%G)
M*,X+XP@^K'BIE)15Y.P)-NR,^N@\->$+_P`0RB0*8+,'YYV'7V4=S^E=?H/P
MUM;0K/J\@NI1SY*9$8/OW;]!]:[=$2-%1%"(HP%48`%>1B<R2]VE]YWT<&WK
M,J:5I-GHMBEG91".->2>I8]R3W-7:**\-MR=V>DDDK(****0PHHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`*E_I6GZFF
MR^LX;@#H70$CZ'J*YF]^&>BW!+6TEQ:GLJOO4?GS^M=C16U.O5I_!)HSG2A/
MXD>:S?"JY4_N-5B<?[<17^1-5/\`A5VN?\_5A_W\?_XBO5:*ZEF.(77\#%X2
MEV/+8OA;JY;][>V2KZJSL?\`T$5HVOPJC!!N]59AW6*(+^I)_E7H-%3+,,0^
MMOD"PE)=#G=/\">']/(86?VEQ_%<-O\`TZ?I70(B1H$10JC@*HP!3J*Y)U)U
<'>3N=$81C\*L%%%%04%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
